Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 3 Astrocytoma 3 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Sarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Melanoma 1 Lymphoma 1 Head and Neck Neoplasms 1 Glioma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Dexamethasone 29 Cyclophosphamide 21 Rituximab 17 Cytarabine 16 Bortezomib 13 Gemcitabine 12 fludarabine 11 Methotrexate 11 Lenalidomide 10 Filgrastim 10 Vincristine 9 Etoposide 9 pomalidomide 8 pembrolizumab 8 Paclitaxel 8 Azacitidine 8 venetoclax 7 carfilzomib 7 Doxorubicin 7 Docetaxel 7 Cyclosporine 7 Calcium Dobesilate 7 Antilymphocyte Serum 7 fludarabine phosphate 6 Topotecan 6 Temozolomide 6 Radiotherapy 6 Peripheral Blood Stem Cell Transplantation 6 Mitoxantrone 6 daratumumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Recurrence × vocimagene amiretrorepvec × Clear all

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡